Bilaketaren emaitzak - Jonathan Webster

  • Erakusten 1 - 13 emaitzak -- 13
Findu emaitzak
  1. 1
    Acute myeloid leukemia in the elderly: therapeutic options and choice

    Acute myeloid leukemia in the elderly: therapeutic options and choice nork Jonathan Webster, Keith W. Pratz

    Argitaratua 2017
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease

    Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease nork Lucy Walkington, Jonathan Webster, B. W. Hancock, Jan Everard, Robert E. Coleman

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Mobile app validation: a digital health scorecard approach

    Mobile app validation: a digital health scorecard approach nork Ramy Sedhom, Michael McShea, Adam B. Cohen, Jonathan Webster, Simon C. Mathews

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea

    A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea nork Jonathan Webster, G. Piscitelli, Anna Polli, Carlo Ferrari, Ikram Shah Ismail, M. F. Scanlon

    Argitaratua 1994
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion.

    Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. nork Sadanori Akita, Jonathan Webster, Shaolei Ren, Hirofumi Takino, Joanne Said, O Zand, Шломо Мелмед

    Argitaratua 1995
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

    DNA methyltransferase inhibitor exposure–response: Challenges and opportunities nork Amanda B. Kagan, Dominique A. Garrison, Nicole M. Anders, Jonathan Webster, Sharyn D. Baker, Srinivasan Yegnasubramanian, Michelle A. Rudek

    Argitaratua 2023
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers

    Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers nork Emily Hofmann, Jonathan Webster, Thuy Do, Reid Kline, Lindsey Snider, Quintin Hauser, Grace Higginbottom, Austin Campbell, Lili Ma, Stefan Paula

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ

    Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ nork Mimansa Sharma, Andrew H. Beck, Jonathan Webster, I Espinosa, Kelli Montgomery, Sushama Varma, Matt van de Rijn, Kristin C. Jensen, Robert B. West

    Argitaratua 2009
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Chaperone Activity of Small Heat Shock Proteins Underlies Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis

    Chaperone Activity of Small Heat Shock Proteins Underlies Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis nork Michael Kurnellas, Sara E. Brownell, Leon Su, Andrey V. Malkovskiy, Jayakumar Rajadas, Gregory Dolganov, Sidharth Chopra, Gary K. Schoolnik, Raymond A. Sobel, Jonathan Webster, Shalina S. Ousman, Rachel A. Becker, Lawrence Steinman, Jonathan B. Rothbard

    Argitaratua 2012
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study

    Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter... nork Jeffrey I. Zwicker, Adam Rojan, Federico Campigotto, Nadia Rehman, Renee Funches, Gregory C. Connolly, Jonathan Webster, Anita Aggarwal, Dalia Mobarek, Charles Faselis, Donna Neuberg, Frederick R. Rickles, Ted Wun, Michael B. Streiff, Alok A. Khorana

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia nork Jonathan Webster, Raoul Tibes, Larry Morris, Amanda L. Blackford, Mark R. Litzow, Mrinal M. Patnaik, Gary L. Rosner, Ivana Gojo, Robert J. Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp, B. Douglas Smith

    Argitaratua 2017
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

    Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML... nork Ivana Gojo, Robert K. Stuart, Jonathan Webster, Amanda L. Blackford, Juan Carlos Varela, Jillian Morrow, Amy E. DeZern, Matthew C. Foster, Mark J. Levis, Catherine C. Coombs, Gabrielle T. Prince, B. Douglas Smith, Hendrik W. van Deventer, Katarzyna Jamieson, Ravi Varadhan, Benjamin G. Vincent, Jonathan S. Serody, Leo Luznik, Joshua F. Zeidner

    Argitaratua 2019
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia nork Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic T. Moore, Karen P. McKinnon, Alec Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: